Since 2013, eight different DAAs regimens have been approved for use in adults with chronic hepatitis C (CHC) infection (table 1) with excellent efficacy (sustained virological response [SVR] rates >90%) and safety profiles. Patients historically considered difficult to treat in the IFN era, such as adults with human immunodeficiency virus co-infection or with hepatitis C virus (HCV)-related compensated cirrhosis, can now be easily treated y, achieving high VR rates after 12 weeks of treatment (1).
The incidence of graft dysfunction and progression to cirrhosis is higher and the overall survival rate is lower in patients transplanted for CHC when compared to patients with other LT indications, but this can now be prevented by achieving SVR before LT (2).
Despite advances in DAA therapy, treatment of children with CHC has remained based on pegylated-IFN with ribavirin (PR) (3) . Although children will typically tolerate the side effects of IFN, its use is a challenge for the patients, their careers, and for the medical team.
It is true that very few children develop end-stage liver disease due to CHC and for most HCVpositive transplanted children the indication for LT is a different underlying condition. Children transplanted with HCV (or who contracted HCV from the graft) have a remarkably better outcome than those transplanted because of HCV (4). In Italy, a national registry studying the natural course of pediatric HCV over 15 years showed that 6/332 (1.8%) children had developed end-stage liver disease at a median age of 9.6 years (5). In our personal experience, however, HCV infection post-LT had a significant impact on these children. This article is protected by copyright. All rights reserved. April 2018 PK 6-18 years of age; (8, 9) efficacy and safety 12-18 years (10, 12) ombitasvir/paritaprevir/rit (FDC) Note: FDC, fixed dose combination; PK, pharmacokinetics.
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